About Cartherics Pty Ltd
The future of cancer treatment, off-the-shelf cellular immunotherapy for cancer. At Cartherics we are developing the next generation of improved and optimized chimeric antigen receptor CAR-T cell products.
We use three unique proprietary approaches to produce individual CAR-T products that can be used by a large number of cancer patients. These three novel technologies set Cartherics apart from other CAR-T companies:
1. Development of CAR-T cells expressing two or more receptors specific for cancer stem cells to avoid the cancer escaping recognition, and also to enhance the attachment and killing by the CAR-T cells.
2. Allogeneic stem cells that can be used for compatible transplants for cancer therapy.
3. Production of a limitless supply of cancer killing CAR-T cells, using proprietary differentiation to create fully functional T cells engineered to contain the selected CAR and T cell receptor (TCR) genes.
Transforming cancer from a fatal disease to a manageable condition.
|
|
|
11-50 employees
View all Cartherics Pty Ltd employees
|
|
Biotechnology
|
|
Level 7 MHTP,Clayton,Victoria,AU
|
|
2014
|
Cartherics Pty Ltd Alternatives
Frequently Asked Questions about Cartherics Pty Ltd
Alan Trounson is the CEO of Cartherics Pty Ltd. To contact Alan Trounson email at [email protected].
Cartherics Pty Ltd Staff Directory
Search Cartherics Pty Ltd Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
